Kezar Life Sciences (KZR) Stock Analysis

What Kezar Life Sciences does

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.

Key metrics

ETFs linked to KZR

Broad-market and Healthcare sector ETFs an investor holding Kezar Life Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KZR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kezar Life Sciences?

Kezar Life Sciences trades under the ticker KZR on NASDAQ.

Which exchange is KZR listed on?

KZR is listed on NASDAQ.

What sector does Kezar Life Sciences operate in?

Kezar Life Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KZR in a portfolio?

PortView shows KZR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.